SABCS 2022

Part 2: Treamtent options in high-risk breast cancer

Part 3: Testing for TROP-2 not needed / no prognostic…

SERDs - who benefits? ESR1 testing required?

New insights: Are CTCs predictive or not?

ADC: Do we need a target? Do we need a predicitve…

monarchE confirms increasing benefit. What are the real…

RIGHT choice against Chemotherapy for aggressive…

Adjuvant TH confirms excellent logn-term follow-up

Chemo without benefit in node-negative disease

Time to reconsider Ki-67 threshold?!

First trial about pregnancy in premenopausal early BC…

Platin-based neoadjuvant therapy in early TNBC: impact…

Benefit of extended adjuvant treatment with endocrine…

Interruption of endocrine therapy in case of desire to…

T-DXd as (neo)adjuvant treatment HR+/HER2- patients

monarchE confirms data once more.

POSITIVE-Trial shwos that temporal therapy interruption…

Good news for young patients

Beneficio del tratamiento hormonal extendido según…

El primer estudio sobre la gestación en pacientes con…

POSITIVE-Trial dimostra che l'interruzione temporanea…

Neoadyuvancia con carboplatino en cáncer de mama precoz…

Highlights on oral SERDS in HR+ mBC

SERENA-2 showed better PFS by camizestrant compared…

A shift from chemotherapy to CDK4/6

Progress in research and clinic

Il miglior approccio per la malattia…

SERENA-2 ha mostrato una migliore PFS grazie a…

RIB + ET appears to be the better option than…

HR+/HER2-: Who still needs chemotherapy?

Ribociclib + endocrine in high risk HR+/HER2- MBC…

CDK4/6 inhibitors - a preferred option also for the…

Endocrine combination despite visceral crisis

Continuing Palbociclib beyond progression does not…

Treatment alternatives to chemotherapy for visceral…

T-DXd new standard after pretreatment with trastuzumab…

Chemotherapy-free (neo)adjuvant treatment seems…

Optimal side effect management required

Important OS update for T-DXd

Positive data for ER+ and HER2+ breast cancer

T-DXd as therapy of choice even after T-DM1 in HER2+…

T-DXd with so far unkown efficacy

T-Dxd keeps us excited

Great data - as usual with T-Dxd

Robust benefit of T-Dxd confirmed with new data

Clinically relevant and statistically significant…

TDXd is the prefered option for pts previously treated…

Beneficio clínicamente y estadísticamente significativo…

TDXd es la primera opción para pacientes tratados…

Positive data for ER+ and HER2+ breast cancer

Importante actualisation des données de survie globale…

Positive data for ER+ and HER2+ breast cancer

A new drug in the endocrine landscape

oral SERDs on the rise?

Positive data for ER+ and HER2+ breast cancer

Une nouvelle molécule dans le traitement hormonal du…

ADC or other therapies after CDK4/6

Positive data for ER+ and HER2+ breast cancer

Olaparib as an alternative to carboplatin in aggressive…

AKT inhibitor capivasertib in HR+ mBC

Estradiol withdrawal affects the micromillieu in the…

CTC count may help in therapy decisions

Promising new player in the second line setting in…

Her2-low discordance rate at 40%

Triple-positive MBC does not require chemotherapy.

Capivasertib - A drug for allcomers

CTCs with metastatic breast cancer re-visited

Le compte des CTC peut orienter la décision…

Obiecująca nowa opcja w drugiej linii zaawansowanego,…

Capivasertib un nuovo standard per tutti?

TNBC - Practice changing data lead to new approvals -…

HER2+ - no new approval but long-term follow up data…

Dealing with Brain mets / Update TNBC

New Indications: ADCs & HER2-low